Stifel Reiterates Buy on Alto Neuroscience, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis reiterated a Buy rating on Alto Neuroscience (NYSE:ANRO) and maintained a $32 price target.
March 25, 2024 | 4:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Paul Matteis reiterated a Buy rating on Alto Neuroscience and maintained a $32 price target.
The reiteration of a Buy rating and maintenance of a $32 price target by a Stifel analyst suggests a strong positive outlook for Alto Neuroscience. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100